Arcutis Biotherapeutics, Inc. (ARQT): who owns it and who trades it
As of Nov 16, 2026, ARQT insiders reported 68 open-market sales worth $13.9M and no purchases in the last 12 months, with 80% of the sale value made under pre-set 10b5-1 plans. The largest seller was Masaru Matsuda (See Remarks), with $3.4M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Arcutis Biotherapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors and Congress mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ARQT
273 funds and institutions reported ARQT shares worth $3.6B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Montanova Capital, LLC with 9.9%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Montanova Capital, LLC | 12.44M | 9.94% | $326M | +1% |
| BlackRock, Inc. | 10.55M | 8.43% | $277M | +15% |
| Frazier Life Sciences Management, L.P. | 9.87M | 7.89% | $259M | No change |
| Rubric Capital Management LP | 8.27M | 6.61% | $217M | No change |
| Polar Capital Holdings Plc | 6.61M | 5.28% | $173M | +17% |
| State Street Corp | 5.82M | 4.66% | $153M | -8% |
| Vanguard Capital Management LLC | 4.99M | 3.99% | $131M | +2% |
| Morgan Stanley | 4.45M | 3.56% | $117M | +6% |
| Jennison Associates LLC | 4.22M | 3.37% | $111M | -15% |
| D. E. Shaw & Co., Inc. | 3.95M | 3.16% | $104M | +58% |
| UBS Group AG | 3.33M | 2.66% | $87.4M | +0% |
| California State Teachers Retirement System | 3.31M | 2.65% | $126M | +2480% |
| Bank of America Corp | 2.99M | 2.39% | $78.3M | +34% |
| Geode Capital Management, LLC | 2.98M | 2.38% | $78.2M | -2% |
| Vanguard Portfolio Management LLC | 2.43M | 1.94% | $63.7M | +24% |
| Orbimed Advisors LLC | 2.04M | 1.63% | $53.5M | – |
| Franklin Resources Inc | 1.93M | 1.54% | $50.6M | -16% |
| American Century Companies Inc | 1.93M | 1.54% | $50.5M | +32% |
| Goldman Sachs Group Inc | 1.67M | 1.33% | $43.7M | +4% |
| Jupiter Topco LLC | 1.41M | 1.13% | $37M | – |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ARQT insiders reported $0 of open-market purchases and $13.9M of sales. 80% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 4, 2026 | Masaru Matsuda | Vice president | Sale plan | 40,000 | $34.32 | $1.4M | Form 4 |
| Nov 2, 2026 | Todd Watanabe | Director | Sale | 4,377 | $31.86 | $139K | Form 4 |
| Nov 2, 2026 | Patrick Burnett | Vice president | Sale | 943 | $31.86 | $30K | Form 4 |
| Nov 2, 2026 | Masaru Matsuda | Vice president | Sale plan | 1,219 | $31.86 | $38.8K | Form 4 |
| Oct 15, 2026 | Howard G. Welgus | Director | Sale plan | 4,728 | $26.93 | $127K | Form 4 |
| Sep 16, 2026 | Masaru Matsuda | See Remarks | Sale plan | 3,674 | $25.00 | $91.8K | Form 4 |
| Sep 15, 2026 | Howard G. Welgus | Director | Sale plan | 4,730 | $24.18 | $114K | Form 4 |
| Sep 8, 2026 | Masaru Matsuda | See Remarks | Sale plan | 9,989 | $25.03 | $250K | Form 4 |
| Aug 27, 2026 | Terrie Curran | Director | Sale | 11,148 | $25.03 | $279K | Form 4 |
| Aug 27, 2026 | Terrie Curran | Director | Sale | 27,052 | $25.03 | $677K | Form 4 |
| Aug 20, 2026 | Terrie Curran | Director | Sale | 1,072 | $26.04 | $27.9K | Form 4 |
| Aug 19, 2026 | Patrick Burnett | See Remarks | Sale | 1,697 | $27.00 | $45.8K | Form 4 |
| Aug 17, 2026 | Howard G. Welgus | Director | Sale plan | 4,730 | $26.18 | $124K | Form 4 |
| Aug 12, 2026 | Patrick Burnett | See Remarks | Sale | 6,700 | $26.08 | $175K | Form 4 |
| Aug 11, 2026 | Patrick Burnett | See Remarks | Sale | 8,300 | $26.52 | $220K | Form 4 |
| Aug 3, 2026 | Patrick Burnett | See Remarks | Sale plan | 955 | $26.12 | $24.9K | Form 4 |
| Aug 3, 2026 | Masaru Matsuda | See Remarks | Sale plan | 1,230 | $26.12 | $32.1K | Form 4 |
| Aug 3, 2026 | Todd Watanabe | Director | Sale plan | 4,375 | $26.12 | $114K | Form 4 |
| Jul 15, 2026 | Howard G. Welgus | Director | Sale plan | 4,730 | $26.91 | $127K | Form 4 |
| Jun 17, 2026 | Howard G. Welgus | Director | Sale plan | 635 | $25.67 | $16.3K | Form 4 |
| Jun 15, 2026 | Sue-Jean Lin | Director | Sale plan | 4,946 | $24.38 | $121K | Form 4 |
| Jun 15, 2026 | Howard G. Welgus | Director | Sale plan | 4,096 | $24.41 | $100K | Form 4 |
| May 11, 2026 | Latha Vairavan | CFO | Sale plan | 435 | $21.05 | $9.2K | Form 4 |
| May 11, 2026 | Patrick Burnett | See Remarks | Sale plan | 222 | $21.05 | $4.7K | Form 4 |
| May 4, 2026 | Masaru Matsuda | See Remarks | Sale plan | 7,372 | $23.27 | $172K | Form 4 |
| May 4, 2026 | Masaru Matsuda | See Remarks | Sale plan | 884 | $23.61 | $20.9K | Form 4 |
| May 4, 2026 | Patrick Burnett | See Remarks | Sale plan | 684 | $23.61 | $16.1K | Form 4 |
| May 4, 2026 | Latha Vairavan | CFO | Sale plan | 1,341 | $23.61 | $31.7K | Form 4 |
| May 4, 2026 | Todd Watanabe | Director | Sale plan | 3,172 | $23.61 | $74.9K | Form 4 |
| May 1, 2026 | Howard G. Welgus | Director | Sale plan | 7,144 | $22.99 | $164K | Form 4 |
| Apr 1, 2026 | Howard G. Welgus | Director | Sale plan | 10,000 | $23.88 | $239K | Form 4 |
| Mar 2, 2026 | Keith R Leonard | Director | Sale plan | 39,272 | $25.39 | $997K | Form 4 |
| Mar 2, 2026 | Howard G. Welgus | Director | Sale plan | 10,000 | $25.65 | $256K | Form 4 |
| Mar 2, 2026 | Larry Todd Edwards | See Remarks | Sale plan | 3,584 | $25.16 | $90.2K | Form 4 |
| Mar 2, 2026 | Larry Todd Edwards | See Remarks | Sale plan | 103 | $25.91 | $2.7K | Form 4 |
| Mar 2, 2026 | Todd Watanabe | Director | Sale plan | 1,068 | $25.91 | $27.7K | Form 4 |
| Mar 2, 2026 | Todd Watanabe | Director | Sale plan | 36,281 | $25.16 | $913K | Form 4 |
| Mar 2, 2026 | Masaru Matsuda | See Remarks | Sale plan | 1,987 | $25.70 | $51.1K | Form 4 |
| Mar 2, 2026 | Masaru Matsuda | See Remarks | Sale plan | 6,553 | $25.16 | $165K | Form 4 |
| Mar 2, 2026 | Masaru Matsuda | See Remarks | Sale plan | 193 | $25.91 | $5K | Form 4 |
| Mar 2, 2026 | Latha Vairavan | CFO | Sale plan | 81 | $25.91 | $2.1K | Form 4 |
| Mar 2, 2026 | Latha Vairavan | CFO | Sale plan | 2,772 | $25.16 | $69.7K | Form 4 |
| Mar 2, 2026 | Patrick Burnett | See Remarks | Sale plan | 6,106 | $25.16 | $154K | Form 4 |
| Mar 2, 2026 | Patrick Burnett | See Remarks | Sale plan | 181 | $25.91 | $4.7K | Form 4 |
| Feb 27, 2026 | Masaru Matsuda | See Remarks | Sale plan | 3,325 | $27.95 | $92.9K | Form 4 |
| Feb 4, 2026 | Patrick Burnett | See Remarks | Sale plan | 9,794 | $25.81 | $253K | Form 4 |
| Feb 2, 2026 | Masaru Matsuda | See Remarks | Sale plan | 7,983 | $25.50 | $204K | Form 4 |
| Feb 2, 2026 | Masaru Matsuda | See Remarks | Sale plan | 4,714 | $25.63 | $121K | Form 4 |
| Feb 2, 2026 | Masaru Matsuda | See Remarks | Sale plan | 19,379 | $25.24 | $489K | Form 4 |
| Feb 2, 2026 | Masaru Matsuda | See Remarks | Sale plan | 8,562 | $24.97 | $214K | Form 4 |
| Feb 2, 2026 | Patrick Burnett | See Remarks | Sale plan | 3,675 | $25.50 | $93.7K | Form 4 |
| Feb 2, 2026 | Todd Watanabe | Director | Sale plan | 19,833 | $25.50 | $506K | Form 4 |
| Feb 2, 2026 | Latha Vairavan | CFO | Sale plan | 1,320 | $25.50 | $33.7K | Form 4 |
| Feb 2, 2026 | Howard G. Welgus | Director | Sale plan | 10,000 | $25.05 | $250K | Form 4 |
| Feb 2, 2026 | Larry Todd Edwards | See Remarks | Sale plan | 2,052 | $25.50 | $52.3K | Form 4 |
| Jan 5, 2026 | Patrick Burnett | See Remarks | Sale plan | 2,490 | $28.98 | $72.2K | Form 4 |
| Jan 2, 2026 | Howard G. Welgus | Director | Sale plan | 10,000 | $28.96 | $290K | Form 4 |
| Dec 31, 2025 | Patrick Burnett | See Remarks | Sale plan | 1,156 | $29.39 | $34K | Form 4 |
| Dec 31, 2025 | Patrick Burnett | See Remarks | Sale plan | 541 | $28.81 | $15.6K | Form 4 |
| Dec 15, 2025 | Patrick Burnett | See Remarks | Sale plan | 11,500 | $28.94 | $333K | Form 4 |
| Dec 1, 2025 | Masaru Matsuda | See Remarks | Sale plan | 1,657 | $30.23 | $50.1K | Form 4 |
| Dec 1, 2025 | Howard G. Welgus | Director | Sale plan | 10,000 | $30.21 | $302K | Form 4 |
| Nov 24, 2025 | Sue-Jean Lin | Director | Sale | 25,272 | $30.78 | $778K | Form 4 |
| Nov 24, 2025 | Todd Watanabe | Director | Sale plan | 48,945 | $30.36 | $1.5M | Form 4 |
| Nov 21, 2025 | Todd Watanabe | Director | Sale plan | 1,055 | $30.00 | $31.6K | Form 4 |
| Nov 20, 2025 | Halley E Gilbert | Director | Sale | 16,532 | $27.55 | $455K | Form 4 |
| Nov 19, 2025 | Masaru Matsuda | See Remarks | Sale plan | 989 | $27.95 | $27.6K | Form 4 |
| Nov 19, 2025 | Masaru Matsuda | See Remarks | Sale plan | 1,561 | $28.50 | $44.5K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Masaru Matsuda | See Remarks | – | $3.4M | Nov 4, 2026 |
| Todd Watanabe | See Remarks, Director | – | $3.3M | Nov 2, 2026 |
| Howard G. Welgus | Director | – | $2.1M | Oct 15, 2026 |
| Patrick Burnett | See Remarks | – | $1.5M | Nov 2, 2026 |
| Keith R Leonard | Director | – | $997K | Mar 2, 2026 |
| Terrie Curran | Director | – | $984K | Aug 27, 2026 |
| Sue-Jean Lin | Director | – | $898K | Jun 15, 2026 |
| Halley E Gilbert | Director | – | $455K | Nov 20, 2025 |
| Latha Vairavan | SVP Chief Financial Officer | – | $146K | May 11, 2026 |
| Larry Todd Edwards | See Remarks | – | $145K | Mar 2, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ARQT short interest
High short interest. 14.4% of ARQT shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went up 3%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 18.16M ARQT shares were sold short, 14.4% of the shares outstanding, down 11.4% from the report before. At the average daily volume of 2.40M shares, buying them all back would take about 7.6 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 18.16M | 14.36% | -11% | 2.40M | 7.6 |
| Oct 15, 2026 | 20.49M | 16.30% | -6% | 2.10M | 9.8 |
| Sep 30, 2026 | 21.69M | 17.26% | +18% | 4.49M | 4.8 |
| Sep 15, 2026 | 18.46M | 14.69% | +11% | 2.16M | 8.5 |
| Aug 31, 2026 | 16.56M | 13.17% | +12% | 1.76M | 9.4 |
| Aug 14, 2026 | 14.72M | 11.71% | +16% | 1.83M | 8.0 |
| Jul 31, 2026 | 12.69M | 10.09% | -6% | 1.18M | 10.7 |
| Jul 15, 2026 | 13.56M | 10.84% | -3% | 1.45M | 9.3 |
| Jun 30, 2026 | 14.02M | 11.21% | -11% | 2.21M | 6.3 |
| Jun 15, 2026 | 15.82M | 12.65% | -2% | 1.58M | 10.0 |
| May 29, 2026 | 16.23M | 12.97% | -8% | 1.92M | 8.4 |
| May 15, 2026 | 17.55M | 14.03% | +4% | 2.40M | 7.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded ARQT
Since Nov 17, 2024, 1 member of Congress reported 2 purchases and 1 sale of ARQT. The latest was a purchase by Gilbert Ray Cisneros, Jr. on May 29, 2026, reported Jun 8, 2026.
Purchases 2Sales 1
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| May 29, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Jun 8, 2026 | Report |
| Mar 3, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Apr 7, 2026 | Report |
| Dec 11, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Partial sale | $1K–$15K | Self | Jan 12, 2026 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Arcutis Biotherapeutics company events
Arcutis Biotherapeutics filed 7 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 4, 2026.
- Nov 4, 2026ResultsReleased financial results. Filing
- Oct 28, 2026LeadershipThe Board of Directors of Arcutis Biotherapeutics, Inc. increased the authorized number of directors on the Board from ten to eleven directors and appointed Dr. Robert Scott as a new member of the Board and the Nominating and Corporate Governance Committee of the Board. Filing
- Aug 5, 2026LeadershipL. Todd Edwards notified Arcutis Biotherapeutics, Inc. of his decision to resign as chief commercial officer of the Company, effective as of August 21, 2026. Filing
- Jul 16, 2026LeadershipThe Board of Directors of Arcutis Biotherapeutics, Inc. increased the authorized number of directors on the Board from nine to ten directors and appointed Mr. Christopher Peetz as a new member of the Board. Filing
- Jun 9, 2026AnnouncementAs part of a regular review of the corporate governance practices of the Company and in an effort to continue to attract and retain qualified members of the Company’s Board of Directors, which includes compensating eligible non-employee directors appropriately for their services, the Compensation… Filing
- Feb 25, 2026ResultsReleased financial results. Filing
- Dec 8, 2025LeadershipMr. Bhaskar Chaudhuri retired from his positions as a member of the Board of Directors of Arcutis Biotherapeutics, Inc. and chair of the Compensation Committee of the Board. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Arcutis Biotherapeutics financials
Famous investors that hold ARQT
4 of the 50 well-known investors we track reported holding ARQT in their latest 13F filing. The largest position is Ken Griffin's, worth $40.5M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 1.53M | $40.5M | 0.0% | +32% |
| Israel Englander · Millennium Management | Q3 2026 | 919,391 | $24.3M | 0.0% | +63% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 476,099 | $12.6M | 0.0% | +715% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 15,357 | $406K | 0.0% | -88% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named ARQT in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 6.1% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 6.1% |
| Oct 5, 2026 | BlackRock, Inc. | 13G/A | 14.1% |
| Oct 5, 2026 | BlackRock, Inc. | 13G/A | 14.1% |
Questions about Arcutis Biotherapeutics, Inc. (ARQT) stock
Who owns the most ARQT stock?
The largest reported owner of Arcutis Biotherapeutics, Inc. (ARQT) is Montanova Capital, LLC, with 9.9% of the company. In total, 273 funds and institutions reported holding ARQT at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are ARQT insiders buying or selling?
In the last 12 months, ARQT insiders reported no open-market purchases and 68 sales worth $13.9M. The latest trade was on Nov 4, 2026. See every trade.
What is the short interest in ARQT?
As of Oct 30, 2026, 18.16M ARQT shares were sold short, 14.4% of the shares outstanding, down 11.4% from the report before. At the average daily volume of 2.40M shares, buying them all back would take about 7.6 trading days (days to cover). See the history.
Have members of Congress traded ARQT?
Yes. 1 member of Congress reported 2 purchases and 1 sale of ARQT since Nov 17, 2024. The latest was reported on Jun 8, 2026. See the trades.
Which famous investors hold ARQT?
4 of the 50 well-known investors we track reported ARQT in their latest 13F filing, including Ken Griffin, Israel Englander, Jim Simons. The largest position is worth $40.5M. See all holders.
Executive pay
Arcutis Biotherapeutics's chief executive was paid a total of $7.2M for the year ended Dec 31, 2025, up 96% from $3.7M the year before. In the last 12 months, Arcutis Biotherapeutics's executives and directors bought no stock on the open market and sold $14.9M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.